Subscribe
Moderna has opened an mRNA facility in Oxfordshire (pictured), but many pharma companies are pulling out of the UK
Image: Moderna
14 October 2025FeaturesEuropeTim Belcher

As investment in UK life sciences wanes, is the sector in trouble?

As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Careers
UK gets new IP minister following cabinet reshuffle
9 September 2025   Wales’ first MP of ethnic minority background brings tech knowledge and expertise to the IP office, which is carrying out two pivotal consultations.
Europe
Pfizer loses UK appeal over Moderna Covid-19 vaccine patent
4 August 2025   UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent.
Europe
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
8 May 2025   Industry body says agreement doesn’t address ‘longstanding industry concerns’ about IP | Deal criticised for ‘lack of detail’ on IP, particularly for UK life sciences and general legal sector | £25.5bn deal offers provisions for medical devices | Smith+Nephew hopes deal will help build trade for healthcare.


Editor's picks

Squires: ‘Inherited patent backlog was an absolute dumpster fire’
Americas
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
1 November 2025

Editor's picks

Americas
Squires: ‘Inherited patent backlog was an absolute dumpster fire’
1 November 2025
Americas
LSPN panel unpacks critical IP risks in deal-making
23 October 2025
Americas
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order
23 October 2025
Americas
Data and delivery: Inside AI's inventorship dilemma
21 October 2025
Americas
Top pharma, biotech, and medtech experts gather at LSPN Fall
21 October 2025
Big Pharma
Moderna TM counsel: Commoditising work using AI is a ‘moral obligation’
16 October 2025

More features

Novartis counsel warns: ‘Don’t let AI develop without our input’
Novo Nordisk counters rival with $9bn bid for obesity drug developer
‘We're being attacked from all sides’: Thermo Fisher Scientific counsel
Is AI emerging as the ‘fourth party’ solving billion-dollar disputes?
The hidden code in life sciences deals
Why AI is changing the patent rules faster than anyone can keep up
LSPN panel unpacks critical IP risks in deal-making
A second bite at the cherry: Adjudicating redesigns after an ITC exclusion order